NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19
According to a preliminary data analysis from a randomized, controlled trial involving 1063 patients, which began on February 21 (known as the Adaptive COVID-19 Treatment Trial, or ACTT) that the hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo. The National Institutes of Health, is the first clinical trial launched in the United States to evaluate an experimental treatment for COVID-19.
Based upon the review of the data, it was noted that remdesivir was better than placebo from the perspective of the primary endpoint, time to recovery, a metric often used in influenza trials. Recovery in this study was defined as being well enough for hospital discharge or returning to normal activity level.
Preliminary results indicate that patients who received remdesivir had a 31% faster time to recovery than those who received placebo (p<0.001). Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo. Results also suggested a survival benefit, with a mortality rate of 8.0% for the group receiving remdesivir versus 11.6% for the placebo group (p=0.059).
Remdesivir, is an investigational broad-spectrum antiviral treatment administered via daily infusion for 10 days. It has shown promise in animal models for treating SARS-CoV-2 (the virus that causes COVID-19) infection and has been examined in various clinical trials.